Literature DB >> 9714354

Cytokines and adhesion molecules in patients with polymyalgia rheumatica.

A Uddhammar1, K G Sundqvist, B Ellis, S Rantapää-Dahlqvist.   

Abstract

Serum levels of interleukin-1beta (IL-1beta), IL-1 receptor antagonist (IL-1ra), tumour necrosis factor alpha (TNF-alpha), IL-6, soluble IL-6 receptor (sIL-6R), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble E-selectin were measured in 15 patients with newly diagnosed polymyalgia rheumatica (PMR) before and after 3 months of corticosteroid therapy. Both IL-6 and IL-1ra were significantly increased in untreated PMR and remained elevated compared with controls during therapy, although significantly only for sIL-1ra. sICAM-1 was raised in 12/15 (87%) patients at diagnosis and remained high in 10/14 (71%) patients; soluble E-selectin levels were initially raised in 6/15 (40%) patients and decreased with therapy in those with the highest levels. IL-6, IL-1ra and sICAM-1 are sensitive indicators of continuing immunological activation in PMR; the advantages of these markers in assessing the response to therapy should be investigated in a longitudinal study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714354     DOI: 10.1093/rheumatology/37.7.766

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  4 in total

1.  A study on soluble intercellular adhesion molecule-1 and selenium in patients with rheumatoid arthritis complicated by vasculitis.

Authors:  Anna Maria Witkowska; Anna Kuryliszyn-Moskal; Maria Halina Borawska; Katarzyna Hukałowicz; Renata Markiewicz
Journal:  Clin Rheumatol       Date:  2003-11-11       Impact factor: 2.980

2.  Clinical use of biologics in vasculitis syndromes.

Authors:  Marino Paroli
Journal:  Biologics       Date:  2012-10-25

Review 3.  Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy.

Authors:  Shunsuke Mori; Yukinori Koga
Journal:  Clin Rheumatol       Date:  2014-05-08       Impact factor: 2.980

Review 4.  Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.

Authors:  Angela G Fleischman
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.